# OnCo record papmet (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/papmet/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "papmet", "NCT02761057" ;
  schema:name "PAPMET (SWOG S1500)"@en ;
  schema:alternateName "PAPMET"@en, "S1500"@en, "SWOG S1500"@en ;
  schema:description "PAPMET was the first randomised trial dedicated to papillary kidney cancer; cabozantinib held the disease back for longer than sunitinib, the previous default, while two more selective MET inhibitors did not."@en ;
  schema:url <https://onco.cc/trials/papmet/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02761057> ;
  onco:status "positive" ;
  onco:tag "subtype-trials" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/papillary-rcc/>, <https://onco.cc/cancers/rcc/> ;
  onco:drugs <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/sunitinib/>, <https://onco.cc/drugs/crizotinib/>, <https://onco.cc/drugs/savolitinib/> ;
  onco:companies <https://onco.cc/companies/exelixis/> ;
  onco:people <https://onco.cc/people/sumanta-pal/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-papmet-pal-lancet-2021/> .